On July 16, 2021 CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, reported that its Chief Medical Officer, Michael Caligiuri, MD, will be presenting at a KOL Webinar on Human Natural Killer (NK) Cell Immunotherapy (Press release, CytoImmune Therapeutics, JUL 16, 2021, View Source [SID1234584904]). The event will feature Jeffrey Miller, M.D. (University of Minnesota) and Michael Caligiuri, M.D. (City of Hope National Medical Center) who will discuss CytoImmune’s approach for human natural killer (NK) cell immunotherapy with a heavy focus on programmed death-ligand 1 (PD-L1)+ NK cell for use in treating lung cancer, and fms-like tyrosine kinase 3 (FLT3) CAR NK cell therapy for use in treating Acute Myeloid Leukemia (AML). A live Q&A session will follow the formal presentations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!